178 Tumor neoantigen prioritization from liquid biopsy whole exome sequencing for selected tumor-infiltrating lymphocyte therapy

178 Tumor neoantigen prioritization from liquid biopsy whole exome sequencing for selected tumor-infiltrating lymphocyte therapy

Bibliografski detalji
Glavni autori:	Li Liu, Simon Turcotte, Shari Pilon-Thomas, Doris Wiener, Brian Czerniecki, Matthew Beatty, Larissa Pikor, Urminder Singh, Christian E Laing, Jacob Gibson, Anna Kluew, Mahdi Golkaram, Sven Bilke, Nathalie Brassard, Stewart E Abbot, Timothy J Langer, Grace DeSantis, Michael J Ciancanelli, Jeff H Tsai
Format:	Članak
Jezik:	English
Izdano:	BMJ Publishing Group 2023-11-01
Serija:	Journal for ImmunoTherapy of Cancer

Slični predmeti

900 TBio BFX 4101: a neoantigen prioritization pipeline for selected tumor-infiltrating lymphocyte therapy
od: Quanyuan He, i dr.
Izdano: (2023-11-01)

346 Expansion and identification of neoantigen reactive tumor infiltrating lymphocytes (TIL) from metastatic colorectal (CRC) and GI cancers
od: Amy Hall, i dr.
Izdano: (2023-11-01)

Tumor neoantigens and tumor immunotherapies
od: Wang Jiani, i dr.
Izdano: (2024-04-01)

Screening tumor stage-specific candidate neoantigens in thyroid adenocarcinoma using integrated exome and transcriptome sequencing
od: Meng Jia, i dr.
Izdano: (2023-10-01)

The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.
od: Mahdi Golkaram, i dr.
Izdano: (2020-11-01)

The Development of Tumor Neoantigen Vaccine Immunotherapy
od: Wang Wanqiu
Izdano: (2019-01-01)

Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
od: Markus W. Löffler, i dr.
Izdano: (2019-04-01)

Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression
od: Kim Bich Nguyen, i dr.
Izdano: (2023-08-01)

A Potent Micron Neoantigen Tumor Vaccine GP‐Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models
od: Zhe Jing, i dr.
Izdano: (2022-08-01)

Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression
od: Stefani Spranger, i dr.
Izdano: (2024-11-01)

Computational Prediction and Validation of Tumor-Associated Neoantigens
od: Vladimir Roudko, i dr.
Izdano: (2020-01-01)

Neoantigen: A New Breakthrough in Tumor Immunotherapy
od: Zheying Zhang, i dr.
Izdano: (2021-04-01)

Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer
od: Brandon Mistretta, i dr.
Izdano: (2023-09-01)

Utilization of primary tumor samples for cancer neoantigen discovery
od: Yong Li, i dr.
Izdano: (2025-01-01)

Tumor neoantigens: from basic research to clinical applications
od: Tao Jiang, i dr.
Izdano: (2019-09-01)

Neoantigen vaccine and neoantigen‐specific cell adoptive transfer therapy in solid tumors: Challenges and future directions
od: Yanwei Shen, i dr.
Izdano: (2022-08-01)

Inducible de novo expression of neoantigens in tumor cells and mice
od: Damo, Martina, i dr.
Izdano: (2021)

Inducible de novo expression of neoantigens in tumor cells and mice
od: Damo, Martina, i dr.
Izdano: (2022)

Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy
od: Truex, Nicholas, i dr.
Izdano: (2020)

Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
od: Berta Segura-Collar, i dr.
Izdano: (2023-05-01)

The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis
od: Zhiting Wei, i dr.
Izdano: (2019-11-01)

mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors
od: Vrunda Trivedi, i dr.
Izdano: (2024-01-01)

The clonal hydra: neoantigen-specific T-cell response in germ cell tumors
od: Shefali Mehra, i dr.
Izdano: (2024-01-01)

Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment
od: Xiaoyu Huang, i dr.
Izdano: (2024-03-01)

Unraveling tumor specific neoantigen immunogenicity prediction: a comprehensive analysis
od: Guadalupe Nibeyro, i dr.
Izdano: (2023-07-01)

Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
od: Berta Segura-Collar, i dr.
Izdano: (2023-07-01)

The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications
od: Ahmet Murat Aydin, i dr.
Izdano: (2021-02-01)

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
od: Shari Pilon-Thomas, i dr.
Izdano: (2023-10-01)

Analysis of Somatic Mutations in the TCGA-LIHC Whole Exome Sequence to Identify the Neoantigen for Immunotherapy in Hepatocellular Carcinoma
od: Swetha Pulakuntla, i dr.
Izdano: (2023-12-01)

Unraveling the power of NAP-CNB’s machine learning-enhanced tumor neoantigen prediction
od: Almudena Mendez-Perez, i dr.
Izdano: (2025-03-01)

TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis
od: Jingcheng Wu, i dr.
Izdano: (2018-08-01)

Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification
od: Celina Tretter, i dr.
Izdano: (2023-08-01)

Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design
od: Kai Xin, i dr.
Izdano: (2024-12-01)

Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy
od: Ting Su, i dr.
Izdano: (2023-08-01)

The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
od: Jiangping Li, i dr.
Izdano: (2023-08-01)

Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood
od: Songming Peng, i dr.
Izdano: (2019-09-01)

TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification
od: Yunxia Tang, i dr.
Izdano: (2020-11-01)

Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth
od: Manisit Das, i dr.
Izdano: (2020-12-01)

The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex
od: Sang Hoon Kim, i dr.
Izdano: (2024-06-01)

1461 Induction of clonal expansion of tumor-reactive T cells and effective tumor suppression by neoantigens predicted from the ‘VACINUS‘ platform
od: Sang Hoon Kim, i dr.
Izdano: (2023-11-01)